4 completed. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
Follow Lung Disease: new trials by email Literature Review of Lung Disease trials Research Report on Lung Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Regional Lung Imaging Using Hyperpolarized Xenon Gas Hyperpolarized xenon - Lung Disease | Phase 1 | Completed | Oxford University Hospitals NHS Trust | 17 | 2012-04-01 | 2022-02-23 |
| To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart AZD3199, Moxifloxacin, Placebo comparator - Chronic Obstructive Pulmonary Disease, Lung Disease | Phase 1 | Completed | AstraZeneca | 40 | 2010-11-01 | 2011-02-16 |
| A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers PF-00610355, moxifloxacin, placebo - Pulmonary Disease, Lung Disease | Phase 1 | Completed | Pfizer | 48 | 2010-06-01 | 2011-01-13 |
| Effects of Endotoxin in Normal Human Volunteers Reference Endotoxin, Inhaled Nitric Oxide - Healthy, Lung Disease | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 198 | 1992-04-06 | 2018-07-05 |
Lung Diseases (4) · Bronchiolitis (1) · Emphysema (1) · Pulmonary Disease, Chronic Obstructive (1) · Respiration Disorders (1) · Sepsis (1) · Shock, Septic (1)
Respiratory Tract Diseases (4) · Infections (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Bronchial Diseases (1) · Bronchitis (1) · Chronic Disease (1) · Disease Attributes (1) · Inflammation (1) · Lung Diseases, Obstructive (1) · Respiratory Tract Infections (1) · Shock (1) · Systemic Inflammatory Response Syndrome (1)
Moxifloxacin (2) · AZD-3199 (1) · N-((4'-hydroxybiphenyl-3-yl)methyl)-2-(3-(2-((-2-hydroxy-2-(4-hydroxy-3-((methylsulfonyl)amino)phenyl)ethyl)amino)-2-methylpropyl)phenyl)acetamide (1)
AstraZeneca (1) · National Institutes of Health Clinical Center (CC) (1) · Oxford University Hospitals NHS Trust (1) · Pfizer (1)
United Kingdom (2) · Belgium (1) · United States (1)
Anthony F Suffredini, M.D. (1) · Carin Jorup, MD (1) · Fergus V Gleeson (1) · Leonard Siew, MB CHB (1)